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least once by a substantial percentage of persons in this study.
These data provide insight into care for persons at the end of
life, particularly among persons with cancer. Furthermore, this
information may be useful as a process indicator of the quality
of end of life care.
GASTROINTESTINAL DISORDERS—Cost Studies
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OBJECTIVES: To estimate: (i) the current rotavirus burden in
New Zealand children less than 5 years of age; and (ii) the annual
health beneﬁts, budget impact and cost- effectiveness of includ-
ing Rotateq, a pentavalent live-attenuated oral rotavirus vaccine,
in the annual Childhood Immunisation Schedule. METHODS:
A spreadsheet model was based on local epidemiology and costs
plus the ﬁndings of a large phase III clinical trial showing that
RotaTeq had 94.5% efﬁcacy against rotavirus hospital presen-
tations and 86.0% against non-urgent medical visits. In the base
case, vaccine uptake was 85% and the annual discount rate was
5%. RESULTS: We predict annually 1356 admissions, 2781 ED
presentations and 9495 primary-care consultations at an annual
societal cost of $7.8M ($27.68/child; two-thirds Government,
one-third caregivers). Vaccinating successive birth cohorts
becomes increasingly effective and cost-effective as more children
become immune. After ﬁve years (assuming 85% annual uptake
of 3 doses), 7936 cases seeking medical attention (1105 admis-
sions, 2215 ED presentations, 6941 primary-care consultations)
would be averted. At an acquisition cost of $50/dose, the incre-
mental cost to Government is $6.41 M in year-1 and $3.35 M in
year-5. Societal cost in year-5 would be $1301 to avert one hos-
pitalisation and $139 to avert one health care presentation. The
annual cost to Government is $3.38 M to avert 7936 cases of
paediatric rotavirus gastroenteritis that would otherwise require
medical attention. The incremental cost and cost/admission
averted are moderately sensitive to rotavirus incidence rates,
declining protection over 5 years (if any), and vaccine unit price,
but robust to uncertainty in other parameters. The budget impact
of vaccination will lessen slightly and the cost-effectiveness will
improve slightly beyond year-5, provided protective efﬁcacy is
maintained in school-aged children. CONCLUSION: Addition
of a pentavalent rotavirus vaccine to the New Zealand Child-
hood Immunisation Schedule would confer important clinical
gains at a modest annual cost.
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PHARMACOECONOMICS OF CHRONIC HEPATITIS C 
IN SLOVAKIA
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OBJECTIVES: To investigate the cost-effectiveness of therapy of
chronic hepatitis C with peginterferon alfa-2b and ribavirin in
the context of the Slovak health care system. METHODS: We
retrospectively obtained clinical data on the cost of treatment in
140 patients with chronic hepatitis C or advanced chronic liver
disease of other etiology. Life-time cost of untreated and treated
chronic hepatitis C was calculated using the Markov model and
cost-effectiveness of antiviral therapy was evaluated by cost per
life-year saved (LYS) analysis. RESULTS: The average medical
cost per patient-year in case of chronic hepatitis C not treated
with antiviral drugs, compensated cirrhosis, complicated cirrho-
sis, and after liver transplantation was 578 USD Sk (33,50 Slovak
crowns = 1 USD), 926 USD, 5890 USD, and 9997 USD, respec-
tively. The cost per life-year saved using 3% discounting was
3156 USD in the average group of patients and 5711 USD in
patients with genotype 1. In patients with genotype 2 and 3
antiviral treatment would result in a life-time cost saving of 492
USD per patient. CONCLUSION: The cost of treatment of
chronic hepatitis C and other chronic liver diseases in Slovakia
is comparable with countries with more advanced economies.
The treatment of chronic hepatitis C with peginterferon alfa-2b
and ribavirin in Slovakia is cost-effective based on pharma-
coeconomic calculations.
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OBJECTIVES: To study the impact of post-operative ileus (POI)
on health care utilization and costs in colectomy surgery patients
in the United States. METHODS: A retrospective cohort study
design was used. Adult patients with a principal procedure code
for colectomy (ICD-9 codes 45.71–45.79), discharged between
Jan. 2004 and Dec. 2004 were identiﬁed from Premier’s Per-
spective Comparative Database, an inpatient records database
from over 500 hospitals in the United States. The colectomy
patients were further classiﬁed for the presence of POI, deﬁned
as presence of paralytic ileus (ICD-9 code 560.1) and/or diges-
tive system complications (ICD-9 code 994.1) during the study
period. Hospital length of stay (LOS), ICU LOS, ventilator
usage, and hospitalization costs were compared using t-tests and
chi-square tests as appropriate. RESULTS: A total of 17,896
patients with primary procedure code for colectomy were iden-
tiﬁed, of which 3115 (17.4%) patients were classiﬁed for pres-
ence of POI, including paralytic ileus (N = 2732; 15.3%) and
digestive system complications (N = 1899; 10.6%), with signif-
icant overlap between the two (N = 1516; 8.5%). A majority of
the patients with POI were male (54.9%), caucasian (70.9%)
and in the 51–64 year age group (51%). The average hospital
LOS was signiﬁcantly higher (p < 0.001) in patients with 
POI (13.6 ± 13.3 days) compared with patients without POI 
(8.6 ± 9.5 days). The average ICU LOS was signiﬁcantly higher
(p < 0.001) in patients with POI (2.4 ± 8.6 days) compared 
with patients without (1.2 ± 9.5 days). Ventilator usage 
was found to be signiﬁcantly higher (p < 0.001) in the POI 
group (17.0%) compared to those without (12.4%). Average
hospitalization costs were signiﬁcantly higher (p < 0.001) in the
patients with POI ($25,089 ± 35,386) than those without POI
($16,907 ± 29,320). CONCLUSION: Post-operative ileus in
colectomy patients is associated with increased hospital resource
utilization. Prevention of POI could reduce hospital length of
stay and costs.
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OBJECTIVES: Health care utilization and costs may be elevated
among patients with C-ONLY and IBS+C. Migraine is an appro-
priate comparator because it is chronic, costly, and non-
gastrointestinal. Health care utilization and costs were evaluated
for these three groups. METHODS: A large US health plan
claims database was retrospectively analyzed from January 2003
through December 2005. Three mutually exclusive cohorts were
identiﬁed: 1) C-ONLY: ICD-9 564.0x (N = 91,632); 2) IBS+C:
ICD-9 564.1 and 564.0x (N = 10,952); and 3) Migraine: ICD-
9 346.xx (N = 101,418). Per patient use and costs (charged
amounts) of medical services and prescriptions were assessed
over a period of 3 months prior to and 9 months following ﬁrst
diagnosis. Patients had continuous health plan enrollment during
this period. RESULTS: Total health care charges were $15,808
and $16,378 for patients with C-ONLY and IBS+C compared to
$10,405 among patients with migraine (difference $5403 and
$5,973, both P < 0.0001). Inpatient charges were approximately
2.5 times higher for the C-ONLY cohort and 1.7 times higher
for the IBS+C cohort compared to migraine ($5112 and $3,625,
vs. $2093; both P < 0.0001). Both cohorts had higher charges
for ofﬁce visits compared to migraine ($2460 and $3,050, vs.
$2282; both P < 0.0001). Charges for hospital outpatient ser-
vices were $3913 and $4738 for patients with C-ONLY and
IBS+C, respectively, compared to $2784 for migraine (both P <
0.0001), while charges for other ancillary services were $2578
and $2627 for C-ONLY and IBS+C, respectively, compared to
$1444 for migraine (both P < 0.0001). Prescription drug charges
were slightly lower for C-ONLY, but higher for IBS+C compared
to migraine ($1438 and $2053 vs. $1551; both P < 0.0001).
Charges for ER visits were higher for both cohorts compared to
migraine ($307 vs. $251, P < 0.0001 and $284 vs. $251, P =
0.0059). CONCLUSION: C-ONLY and IBS+C are costly con-
ditions that present greater economic burden to payers compared
to migraine. Institutional costs are primary drivers for constipa-
tion expenditures.
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COST OF PATIENT CARE IN PATIENTS WITH CROHN`S
DISEASE IN BRAZIL: PUBLIC HEALTH PERSPECTIVE
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OBJECTIVES: Because of its long duration, Crohn`s disease
(CD) causes high use of health services and high lifetime costs
for medical care. The aim of the present study was to measure
the annual costs of patients with CD from the Brazilian public
heath perspective and to identify potentially relevant determi-
nants of costs. METHODS: Thirty one gastroenterologists from
southeast Brazil prospectively evaluated all their CD patients
during two months. They used a structured questionnaire specif-
ically developed to evaluate resource use by patients with CD.
Costs of medical services (diagnostics and treatment) were con-
sidered as well as costs of medication. Resource use was valued
using government reimbursement for hospital services and gov-
ernment tender prices for drugs. RESULTS: 221 patients were
evaluated. The mean annual cost of one CD patient was R$
2.239,67, including medication, physician, laboratory, diagnos-
tic procedures, hospitalization and surgery costs. Medication,
hospitalization, surgery and laboratory/ diagnostic procedures
accounted, respectively for 79%, 18%, 2% and 1% of the total
annual costs. Mesalazine was the most used drug to initiate CD`s
treatment (59% of the times). Although mesalazine is deemed to
be more expensive than sulfasalazine, there was no statistical dif-
ference between the costs of the patients treated with mesalazine
and sulfasalazine. In fact, due to differences in the mean dosage
of theses drugs, mesalazine daily cost is lower than sulfasalazine.
CONCLUSION: This is the ﬁrst time that CD treatment costs
have been demonstrated from the Brazilian public health per-
spective. Considering that there was no statistical difference in
total costs among patients taking mesalazine and sulfasalazine,
and that medications represent more than 70% of total CD treat-
ment annual costs in the public Brazilian health care system, the
use of mesalazine may represent a reduction factor in the ﬁnan-
cial resource expenditure for the treatment of CD.
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OBJECTIVES: To investigate the potential impact of non-
adherence resulting from multiple daily dosing on cost-utility of
gastrointestinal prophylaxis strategies in preventing NSAID
associated gastrointestinal complications. METHODS: Two
decision analytical models (TreeAge 2005) were developed—one
model incorporating non-adherence resulting from multiple daily
dosing and another model that does not. Each model evaluates
the cost-utility of gastrointestinal prophylaxis in a hypothetical
cohort of patients’ age ≥65 years beginning a 6 month course of
NSAIDs. Patients entering each model were treated with either:
(1.) No Prophylaxis, (2.) Proton Pump Inhibitors (generic
omeprazole od) (3.) misoprostol (200 ug qid), (4.) ranitidine (300
mg bid). Average adherence to therapy: od = 79% ± 14%, bid =
69% ± 15% and qid = 51% ± 20% were obtained from a sys-
tematic review of studies using electronic monitoring devices.
Costs were from the perspective of a 3rd party payer of a Cana-
dian provincial seniors’ drug plan. Cost-Utility was measured 
in terms of cost per quality adjusted life year (QALY) gained, 
relative to no prophylaxis. Probabilistic sensitivity analysis 
using Monte Carlo Simulation was used to generate uncertainty
of results, along with cost-effectiveness acceptability curves.
RESULTS: Misoprostol (200 ug qid) has a greater likelihood
(69.2%) than generic omeprazole (30.8%) of being the optimal
cost-effective strategy at a willingness to pay (WTP) of $50,000
per QALY in the model that does not incorporate non-adherence
resulting from multiple daily dosing. In the model that incorpo-
rates non-adherence resulting from multiple daily dose regimens,
generic omeprazole has a greater likelihood (94.8%) than miso-
prostol (5.2%) of being the optimal cost-effective strategy at a
WTP of $50,000 per QALY. CONCLUSION: Cost-utility results
are sensitive to non-adherence resulting from multiple-daily
dosing. Previous economic models in this area have not incor-
porated this in the analysis. Markov modeling or discrete event
simulation may be better suited to incorporate non-adherence
rates of therapies.
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